Outcome of immunosuppression in children with IgA vasculitis-related nephritis.
Katharina RohnerMatko MarlaisYo Han AhnAlaa AliAbrar AlshariefAnja Blejc NovakMarta BrambillaEvrim Kargin CakiciCengiz CandanNur CanpolatEugene Yu-Hin ChanStéphane DecramerMadeleine DidsburyFilipa DuraoAnne M DurkanAli DüzovaThomas ForbesValentina GracchiTulin GüngörTomoko HorinouchiBelde Kasap DemirYasuko KobayashiMikael KoskelaEda Didem Kurt SukurClaudio La ScolaDean LanganXiaozhong LiGabriele MalgieriAntonio MastrangeloJeesu MinMalgorzata Mizerska-WasiakNabila MoussaouiAytul NoyanMatti NuutinenJennifer O'GormonTakayuki OkamotoLouise OniMichiel OosterveldMalgorzata Pańczyk-TomaszewskaGonul ParmaksizAndrea PasiniPornpimol RianthavornJoris RoelofsYunyan ShenRajiv SinhaRezan TopaloğluDiletta Domenica TorresTomohiro UdagawaMartin WennerströmYok Chin YapKjell TullusPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
In this large retrospective cohort, key features associated with disease outcome are highlighted. Importantly, there was no evidence to support that any specific immunosuppressive treatments were superior to others. Further discovery science and well-conducted clinical trials are needed to define accurate treatment and improve outcomes of IgAVN.